New research reveals that individuals who come off new slimming jabs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Findings released in a prominent medical journal demonstrates that while obese individuals often shed a large proportion of their body weight while using the jabs, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing such drugs must be informed of the potential of quick rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to starting weight in about 18 months.
Comparing Approaches
The research, which reviewed dozens of trials involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with older methods.
The team note that people who shed pounds through dieting typically have a slower creep back—approximately 0.1 kg a month—once they finish.
Understanding the Rapid Rebound
Nutrition scientists suggest the mode of action of the jabs accounts for the accelerated weight return.
The injections imitate a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of the hormone concentrations far above than the body's typical production may cause the system to produce less of its endogenous GLP-1, and may also reduce responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication leads to hunger is no longer kept in check, making binge eating much more probable."
A Chronic Issue?
The NHS recommend the injections for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Professionals say that, due to the significant potential of relapse, the therapy should be considered ongoing.
This perspective is supported by drug manufacturers, who note that the findings "emphasize the chronic nature of excess weight," similar to managing diseases like hypertension.
User Experiences
Individuals who have discontinued the medication explain a intense return of cravings.
"It felt as if a trigger that goes on and I was suddenly starving," described an individual.
This challenge is worsened if patients have not developed sustainable lifestyle or habit modifications during treatment.
Significant Interest
Recent estimates indicate that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is higher among females than men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while the jabs are powerful agents for shedding pounds, they are not a permanent cure and long-term success likely depends on integrated behavioural management.
